← Back to All Services

AI-Driven Drug Discovery (AIDD) Services

Revolutionizing pharmaceutical research with machine learning, deep learning, and autonomous AI agents

At BioCogniz, we harness the power of artificial intelligence to accelerate every stage of the drug discovery pipeline. Our cutting-edge AI-driven drug discovery (AIDD) platform combines state-of-the-art machine learning, deep learning architectures, and autonomous AI agents to dramatically reduce time, cost, and failure rates in pharmaceutical development.

Why AI-Driven Drug Discovery?

Traditional drug discovery is expensive (averaging $2.6 billion per approved drug), time-consuming (10-15 years), and has a staggering 90% failure rate. AI transforms this paradigm by:

Our Comprehensive AIDD Services

1. ML-Based ADMET Prediction

Predictive modeling is the foundation of modern drug discovery. Our proprietary machine learning models predict critical ADMET properties with industry-leading accuracy:

Our ML Models:

• Random Forests & Gradient Boosting: For tabular molecular descriptor data
• Deep Neural Networks (DNN): Multi-task learning for simultaneous prediction of multiple ADMET endpoints
• Graph Neural Networks (GNN): Direct molecular graph learning (MPNN, GAT, GCN architectures)
• Transformer-based Models: SMILES and molecular fingerprint sequence modeling
• Ensemble Methods: Combining multiple models for robust, calibrated predictions

Validation: All models are rigorously validated on external test sets, time-split validation, and scaffold splits to ensure generalization to novel chemical space.

2. Deep Learning Generative Design

Our generative AI platform designs novel molecules with desired properties from scratch. This isn't just screening—it's true de novo design.

Generative Architectures We Use:

• Variational Autoencoders (VAEs): Continuous latent space for smooth chemical space exploration
• Generative Adversarial Networks (GANs): Generate realistic, drug-like molecules
• Recurrent Neural Networks (RNNs/LSTMs): SMILES string generation
• Transformer Models: GPT-style molecular generation with attention mechanisms
• Graph-based Generative Models: Direct molecular graph generation (MolGAN, GraphVAE)
• Diffusion Models: State-of-the-art generative modeling for 3D molecular conformations

Capabilities:

• Target-Specific Design: Generate molecules optimized for specific protein targets
• Multi-Objective Optimization: Balance potency, selectivity, ADMET, and synthetic accessibility
• Scaffold Hopping: Discover novel scaffolds with similar bioactivity
• Lead Optimization: Iteratively improve existing compounds
• Bioisosteric Replacement: AI-suggested bioisosteres for property optimization
• Constrained Generation: Enforce substructure constraints, exclude toxic moieties

Reinforcement Learning for Optimization:

We employ reinforcement learning (RL) algorithms to fine-tune generation towards specific objectives:

• Policy gradient methods (REINFORCE, PPO)
• Q-learning approaches
• Multi-objective RL for balancing competing properties
• Reward shaping with medicinal chemistry expertise

3. Virtual Screening & Molecular Docking

Screen millions of compounds or design libraries against your target protein with AI-enhanced precision.

Virtual Screening Services:

• Ultra-large library screening (billions of compounds)
• Fragment-based virtual screening
• Focused library design and screening
• Natural product database screening
• Repurposing screens for known drugs
• PAINS filter and drug-likeness filtering

AI-Enhanced Scoring:

• Classical Scoring Functions: AutoDock Vina, Proprietary scroing functions
• ML-Based Rescoring: Train custom scoring functions on your experimental data
• Deep Learning Scoring: 3D CNNs for binding affinity prediction
• Physics-Based Methods: MM-PBSA, MM-GBSA free energy calculations
• Consensus Scoring: Combine multiple methods for higher hit rates

Molecular Docking Services:

• High-throughput docking for virtual screening campaigns
• Induced-fit docking for flexible protein-ligand interactions
• Covalent docking for irreversible inhibitors
• Ensemble docking accounting for protein flexibility
• AI-enhanced scoring and pose selection

Molecular Dynamics Simulations:

• Protein-ligand binding free energy calculations (FEP, TI)
• Conformational sampling and flexibility analysis
• Allosteric site identification
• Residence time prediction
• AI-accelerated MD with enhanced sampling techniques

AI Agents Workflow for Drug Discovery

The future of drug discovery is agentic. Our autonomous AI agents can:

Our AI agents workflow represents a paradigm shift from AI as a tool to AI as an active collaborator in the discovery process.

Key Benefits

Our AI-DD Technology Stack

We combine the best open-source tools with our proprietary algorithms:

Open Source Tools:

• Molecular Modeling: RDKit, OpenBabel, OpenEye Toolkits
• Docking: AutoDock Vina, Smina
• MD Simulations: GROMACS, AMBER, OpenMM, NAMD
• ML Frameworks: PyTorch, TensorFlow, Scikit-learn
• Cheminformatics: DeepChem, Chemprop, MoleculeNet

Proprietary Tools:

• BioCogniz AI-ADMET™ - Our advanced ADMET prediction suite
• BioCogniz GenDrug™ - Proprietary generative design platform
• BioCogniz SmartDock™ - AI-enhanced molecular docking
• BioCogniz AgentDD™ - Autonomous drug discovery agents

Case Studies & Success Stories

Case Study 1: Kinase Inhibitor Development

Challenge: A biotech company needed to identify selective inhibitors for a novel kinase target with minimal off-target activity.

Solution: We used our generative AI platform to design 500 novel compounds, combined with selectivity prediction models trained on kinase family data.

Results:

• Identified 12 highly selective candidates in 4 weeks
• 3 compounds showed sub-nanomolar potency in wet lab validation
• 95% reduction in screening costs compared to HTS approach

Case Study 2: ADMET Optimization

Challenge: Promising lead compound had poor oral bioavailability and hERG liability.

Solution: Applied our ML-based ADMET prediction combined with generative design to optimize the scaffold.

Results:

• Generated 50 optimized analogs maintaining potency
• Improved bioavailability from 8% to 62%
• Eliminated hERG liability while retaining target activity

Frequently Asked Questions

Related Services